ArticleBMC rheumatology2025
Neoplasm related mortality risk in Systemic Sclerosis: a nationwide study.
Article in BMC rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Malignancy in Systemic Sclerosis: A Multicenter Retrospective Study.Biomedicines · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe higher mortality rates in patients with Systemic sclerosis (SSc) are related to SSc activity, cardiovascular disease, and neoplasms, among other factors. Our objective was to assess the impact of solid organ neoplasms (SON) and hematological neoplasms (HN) on mortality among SSc patients.
methodsA retrospective, observational comparison of SON and HN-related deaths in SSc patients with those in the general Spanish population was conducted using data from the Spanish Hospital Discharge Database. Binary logistic regression was used to analyze the impact of SSc on mortality risk from each neoplasm.
resultsDuring 2016-2019, 139,531 in-hospital deaths from neoplasms were certified in Spain (67 in patients with SSc). Malignancies accounted for 9.7% of all deaths in SSc patients, and disease activity for 11.5% (p > 0.05). Compared to the general Spanish population, patients with SSc had a higher death ratio from lung neoplasms (18.6 vs. 25.4%, OR = 2.228, 95% CI 1.260-3.937), gynecological neoplasms (3 vs. 13.4%, OR = 4.804, 95%CI 2.372-9.730), attributable to the increased risk of uterine tumors (0.9 vs. 4.5%, OR = 6.177, 95% CI 1.931-19.758) and ovarian carcinomas (1.3 vs. 4.5%, OR = 3.456, 95% CI 1.083-11.032), and from T/NK lineage lymphomas (0.3 vs. 3.0%, OR = 8.955 95% CI: 2.181-36.767).
conclusionThe detection of chronic comorbidities such as cancer is emerging as a noteworthy component of standard care for SSc patients. This can be addressed during their follow up or even in specific screening programs aimed at achieving better long-term quality of life and prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.